Use a written protocol and, where possible, calibrated dispensing instead of freehand syringe draws
Demand for GLP-1 therapies has increased sharply, driven largely by obesity treatment
Its not a biohack shortcut, but early data on brain function and cellular aging are promising
By incorporating fibre and protein in their new offerings, can restaurants and supermarkets take a meaningful slice out of the GLP-1 pie
This aligns closely with the approximately 15% average weight loss seen with injectable Wegovy in earlier phase 3 trials, although the studies were not head-to-head and involved different designs and populations
These signs and symptoms can also occur among patients taking normal doses of the medication as well as in overdoses, she added